Hauser, Robert A. published the artcileFuture Treatments for Parkinson’s Disease: Surfing the PD Pipeline, HPLC of Formula: 377727-87-2, the publication is International Journal of Neuroscience (2011), 121(S2), 53-62, database is CAplus and MEDLINE.
A review. Our current wish list for the treatment of Parkinson’s disease (PD) includes therapies that will provide robust and sustained antiparkinsonian benefit through the day, ameliorate or prevent dyskinesia, and slow or prevent the progression of the disease. In this article, I review selected new therapies in clin. development for motor features or treatment complications of PD, and some that may slow disease progression. These include adenosine 2a (A2a) antagonists (istradefylline, preladenant, and SYN115), levodopa/carbidopa intestinal gel (LCIG), IPX066-an extended-release formulation of carbidopa/levodopa, XP21279-a sustained-release levodopa prodrug, ND0611-a carbidopa s.c. patch, safinamide-a mixed mechanism of action medication that may provide both MAO-B and glutamate inhibition, PMY50028-an oral neurotrophic factor inducer, antidyskinesia medications (AFQ056 and fipamezole), and gene therapies (AAV2-neurturin and glutamic acid decarboxylase gene transfer). Some of these therapies will never be proven efficacious and will not come to market while others may play a key role in the future treatment of PD.
International Journal of Neuroscience published new progress about 377727-87-2. 377727-87-2 belongs to triazoles, auxiliary class GPCR/G Protein,Adenosine Receptor, name is 2-(Furan-2-yl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)piperazin-1-yl)ethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, and the molecular formula is C25H29N9O3, HPLC of Formula: 377727-87-2.
Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics